Risedronate And Ergocalciferol Prevent Hip Fracture In Elderly Men With Parkinson Disease
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 121 |
| Sex | Both Genders |
| Age Range | 65+ |
| Body Types | Overweight, Average |
Two years supplementation of 1,000 IU of vitamin D2 was unable to prevent hip fractures and preserve bone mineral density in persons with Parkinson's disease, while the active group of Risedronate plus vitamin D2 was effective.
